Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Gastrointestinal Therapeutics Market, by Type
1.4.2 North America Gastrointestinal Therapeutics Market, by Distribution Channel
1.4.3 North America Gastrointestinal Therapeutics Market, by Route of Administration
1.4.4 North America Gastrointestinal Therapeutics Market, by Application
1.4.5 North America Gastrointestinal Therapeutics Market, by Drug Class
1.4.6 North America Gastrointestinal Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Gastrointestinal Therapeutics Market
Chapter 4. North America Gastrointestinal Therapeutics Market by Type
4.1 North America Branded Market by Country
4.2 North America Generics Market by Country
Chapter 5. North America Gastrointestinal Therapeutics Market by Distribution Channel
5.1 North America Retail Pharmacies Market by Country
5.2 North America Hospital Pharmacies Market by Country
5.3 North America Online Pharmacies Market by Country
Chapter 6. North America Gastrointestinal Therapeutics Market by Route of Administration
6.1 North America Injectable Market by Country
6.2 North America Oral & Others Market by Country
Chapter 7. North America Gastrointestinal Therapeutics Market by Application
7.1 North America Crohn's Disease Market by Country
7.2 North America Ulcerative Colitis Market by Country
7.3 North America GERD Market by Country
7.4 North America IBS Market by Country
7.5 North America Others Market by Country
Chapter 8. North America Gastrointestinal Therapeutics Market by Drug Class
8.1 North America Biologics/Biosimilar Market by Country
8.2 North America Anti-Diarrheal Market by Country
8.3 North America Anti-Emetics Market by Country
8.4 North America Digestive Enzymes Market by Country
8.5 North America Aminosalicylates Market by Country
8.6 North America Proton Pump Inhibitors Market by Country
8.7 North America Laxatives & H2 Antagonists Market by Country
8.8 North America Others Market by Country
Chapter 9. North America Gastrointestinal Therapeutics Market by Country
9.1 US Gastrointestinal Therapeutics Market
9.1.1 US Gastrointestinal Therapeutics Market by Type
9.1.2 US Gastrointestinal Therapeutics Market by Distribution Channel
9.1.3 US Gastrointestinal Therapeutics Market by Route of Administration
9.1.4 US Gastrointestinal Therapeutics Market by Application
9.1.5 US Gastrointestinal Therapeutics Market by Drug Class
9.2 Canada Gastrointestinal Therapeutics Market
9.2.1 Canada Gastrointestinal Therapeutics Market by Type
9.2.2 Canada Gastrointestinal Therapeutics Market by Distribution Channel
9.2.3 Canada Gastrointestinal Therapeutics Market by Route of Administration
9.2.4 Canada Gastrointestinal Therapeutics Market by Application
9.2.5 Canada Gastrointestinal Therapeutics Market by Drug Class
9.3 Mexico Gastrointestinal Therapeutics Market
9.3.1 Mexico Gastrointestinal Therapeutics Market by Type
9.3.2 Mexico Gastrointestinal Therapeutics Market by Distribution Channel
9.3.3 Mexico Gastrointestinal Therapeutics Market by Route of Administration
9.3.4 Mexico Gastrointestinal Therapeutics Market by Application
9.3.5 Mexico Gastrointestinal Therapeutics Market by Drug Class
9.4 Rest of North America Gastrointestinal Therapeutics Market
9.4.1 Rest of North America Gastrointestinal Therapeutics Market by Type
9.4.2 Rest of North America Gastrointestinal Therapeutics Market by Distribution Channel
9.4.3 Rest of North America Gastrointestinal Therapeutics Market by Route of Administration
9.4.4 Rest of North America Gastrointestinal Therapeutics Market by Application
9.4.5 Rest of North America Gastrointestinal Therapeutics Market by Drug Class
Chapter 10. Company Profiles
10.1 Abbott Laboratories
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expense
10.1.5 SWOT Analysis
10.2 AbbVie, Inc.
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Approvals and Trials:
10.3 Takeda Pharmaceutical Company Limited
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional Analysis
10.3.4 Research & Development Expense
10.3.5 Recent strategies and developments:
10.3.5.1 Partnerships, Collaborations, and Agreements:
10.3.5.2 Acquisition and Mergers:
10.4 Pfizer, Inc.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Regional & Segmental Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Partnerships, Collaborations, and Agreements:
10.5 Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Segmental and Regional Analysis
10.5.4 Research & Development Expense
10.5.5 Recent strategies and developments:
10.5.5.1 Product Launches and Product Expansions:
10.6 Johnson & Johnson (Janssen Global Services, LLC)
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental &Regional Analysis
10.6.4 Research & Development Expenses
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 AstraZeneca PLC
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Regional Analysis
10.7.4 Research & Development Expenses
10.8 Bayer AG
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental and Regional Analysis
10.8.4 Research & Development Expense
10.9 Sun Pharmaceutical Industries Ltd.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Research & Development Expenses
10.10. Cipla Limited
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Regional Analysis
10.10.4 Research & Development Expense
Unique Offerings 
